Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 141396-28-3
Drug Levels and Effects
Summary of Use during Lactation
Because argatroban is poorly absorbed orally, it might not adversely affect a breastfeeding infant. However, no information is available on the use of argatroban during breastfeeding, so an alternate drug is preferred.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Acenocoumarol, Dalteparin, Enoxaparin, Heparin, Rivaroxaban, Warfarin
Substance Identification
Substance Name
Argatroban
CAS Registry Number
141396-28-3
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl++ +) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid.[Biochemistry. 1984]Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl++ +) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid.Kikumoto R, Tamao Y, Tezuka T, Tonomura S, Hara H, Ninomiya K, Hijikata A, Okamoto S. Biochemistry. 1984 Jan 3; 23(1):85-90.
- Synthesis of monomeric and polymeric conjugates carrying a thrombin inhibitor through an ester bond.[J Biomed Mater Res. 1998]Synthesis of monomeric and polymeric conjugates carrying a thrombin inhibitor through an ester bond.Noguchi H, Iwata H, Ikada Y. J Biomed Mater Res. 1998 Mar 15; 39(4):621-9.
- Review Lovastatin.[Drugs and Lactation Database (...]Review Lovastatin.. Drugs and Lactation Database (LactMed®). 2006
- Review Quniupristin-Dalfopristin.[Drugs and Lactation Database (...]Review Quniupristin-Dalfopristin.. Drugs and Lactation Database (LactMed®). 2006
- Review Peramivir.[Drugs and Lactation Database (...]Review Peramivir.. Drugs and Lactation Database (LactMed®). 2006
- Argatroban - Drugs and Lactation Database (LactMed®)Argatroban - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...